Indoleamine 2,3-dioxygenase in transplantation

Nephrology

Volumn 13, Issue 3, 2008, Pages 204-211

  Mulley, William R ^a   Nikolic Paterson, David J ^b  

^a MONASH MEDICAL CENTRE   (Australia)

^b NONE

Author keywords

Dendritic cell; Kynurenine; Macrophage; Transplantation tolerance; Tryptophan

Indexed keywords

ABATACEPT; BELATACEPT; INDOLEAMINE 2,3 DIOXYGENASE; TRYPTOPHAN;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CATABOLISM; DENDRITIC CELL; DRUG BINDING; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; ANTIOXIDANTS; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON TYPE II; KYNURENINE; LYMPHOCYTE SUBSETS; MACROPHAGES; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE; TRYPTOPHAN;

EID: 40349103377     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2007.00921.x     Document Type: Review

References (62)

1. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol. Cell. Biol. 2003 81 : 247 65.
2. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 2004 4 : 762 74.
3. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. Faseb J. 1991 5 : 2516 22.
4. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 2002 3 : 1097 101.
5. Fallarino F, Grohmann U, Hwang KW, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 2003 4 : 1206 12.
6. Logan GJ, Smyth CM, Earl JW, et al. HeLa cells cocultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through up-regulation of indoleamine 2,3-dioxygenase activity. Immunology 2002 105 : 478 87.
7. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998 281 : 1191 3.
8. Kwidzinski E, Bunse J, Aktas O, et al. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. Faseb J. 2005 19 : 1347 9.
9. Sakurai K, Zou JP, Tschetter JR, Ward JM, Shearer GM. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2002 129 : 186 96.
10. Choi BK, Asai T, Vinay DS, Kim YH, Kwon BS. 4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms. Cytokine 2006 34 : 233 42.
11. Schroecksnadel K, Zangerle R, Bellmann-Weiler R, Garimorth K, Weiss G, Fuchs D. Indoleamine-2,3-dioxygenase and other interferon-gamma-mediated pathways in patients with human immunodeficiency virus infection. Curr. Drug. Metab. 2007 8 : 225 36.
12. Boasso A, Shearer GM. How does indoleamine 2,3-dioxygenase contribute to HIV-mediated immune dysregulation. Curr. Drug. Metab. 2007 8 : 217 23.
13. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 2007 117 : 1147 54.
14. Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 2002 107 : 452 60.
15. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 1999 189 : 1363 72.
16. von Bubnoff D, Matz H, Frahnert C, et al. FcepsilonRI induces the tryptophan degradation pathway involved in regulating T cell responses. J. Immunol. 2002 169 : 1810 6.
17. Bauer TM, Jiga LP, Chuang JJ, Randazzo M, Opelz G, Terness P. Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl. Int. 2005 18 : 95 100.
18. Terness P, Bauer TM, Rose L, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 2002 196 : 447 57.
19. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002 9 : 1069 77.
20. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 2002 196 : 459 68.
21. Munn DH, Mellor AL, Rossi M, Young JW. Dendritic cells have the option to express IDO-mediated suppression or not. Blood 2005 105 : 2618.
22. Terness P, Chuang JJ, Opelz G. The immunoregulatory role of IDO-producing human dendritic cells revisited. Trends Immunol. 2006 27 : 68 73.
23. Fleckner J, Martensen PM, Tolstrup AB, Kjeldgaard NO, Justesen J. Differential regulation of the human, interferon inducible tryptophanyl-tRNA synthetase by various cytokines in cell lines. Cytokine 1995 7 : 70 7.
24. Tolstrup AB, Bejder A, Fleckner J, Justesen J. Transcriptional regulation of the interferon-gamma-inducible tryptophanyl-tRNA synthetase includes alternative splicing. J. Biol. Chem. 1995 270 : 397 403.
25. Seymour RL, Ganapathy V, Mellor AL, Munn DH. A high-affinity, tryptophan-selective amino acid transport system in human macrophages. J. Leukoc. Biol. 2006 80 : 1320 7.
26. Sono M, Taniguchi T, Watanabe Y, Hayaishi O. Indoleamine 2,3-dioxygenase. Equilibrium studies of the tryptophan binding to the ferric, ferrous, and CO-bound enzymes. J. Biol. Chem. 1980 255 : 1339 45.
27. Hayaishi O. Utilization of superoxide anion by indoleamine oxygenase-catalyzed tryptophan and indoleamine oxidation. Adv. Exp. Med. Biol. 1996 398 : 285 9.
28. Thomas SR, Stocker R. Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep. 1999 4 : 199 220.
29. Christen S, Thomas SR, Garner B, Stocker R. Inhibition by interferon-gamma of human mononuclear cell-mediated low density lipoprotein oxidation. Participation of tryptophan metabolism along the kynurenine pathway. J. Clin. Invest. 1994 93 : 2149 58.
30. Liu H, Liu L, Fletcher BS, Visner GA. Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury. Am. J. Respir. Crit. Care Med. 2006 173 : 566 72.
31. Thomas SR, Mohr D, Stocker R. Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. J. Biol. Chem. 1994 269 : 14457 64.
32. Thomas SR, Terentis AC, Cai H, et al. Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J. Biol. Chem. 2007 282 : 23778 87.
33. Li Y, Tredget EE, Ghahary A. Cell surface expression of MHC class I antigen is suppressed in indoleamine 2,3-dioxygenase genetically modified keratinocytes: implications in allogeneic skin substitute engraftment. Hum. Immunol. 2004 65 : 114 23.
34. Beutelspacher SC, Pillai R, Watson MP, et al. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur. J. Immunol. 2006 36 : 690 700.
35. Brandacher G, Cakar F, Winkler C, et al. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int. 2007 71 : 60 7.
36. Guillonneau C, Hill M, Hubert FX, et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J. Clin. Invest. 2007 117 : 1096 106.
37. Sakurai K, Zou JP, Torres NI, Tschetter JR, Kim HS, Shearer GM. Study of the effect of indoleamine 2,3-dioxygenase on murine mixed lymphocyte reactions and skin allograft rejection. Transplant. Proc. 2002 34 : 3271 3.
38. Reding R, Davies HF. Revisiting liver transplant immunology: from the concept of immune engagement to the dualistic pathway paradigm. Liver Transpl. 2004 10 : 1081 6.
39. Miki T, Sun H, Lee Y, et al. Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts. Transplant. Proc. 2001 33 : 129 30.
40. Pan TL, Lin CL, Chen CL, et al. Identification of the indoleamine 2,3-dioxygenase nucleotide sequence in a rat liver transplant model. Transpl. Immunol. 2000 8 : 189 94.
41. Alexander AM, Crawford M, Bertera S, et al. Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 2002 51 : 356 65.
42. Li Y, Tredget EE, Ghaffari A, Lin X, Kilani RT, Ghahary A. Local expression of indoleamine 2,3-dioxygenase protects engraftment of xenogeneic skin substitute. J. Invest. Dermatol. 2006 126 : 128 36.
43. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J. Immunol. 1991 147 : 2461 6.
44. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990 248 : 1349 56.
45. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991 174 : 561 9.
46. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 2001 19 : 225 52.
47. Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 2006 24 : 233 8.
48. Elster EA, Hale DA, Mannon RB, Cendales LC, Swanson SJ, Kirk AD. The road to tolerance: renal transplant tolerance induction in nonhuman primate studies and clinical trials. Transpl. Immunol. 2004 13 : 87 99.
49. Belladonna ML, Grohmann U, Guidetti P, et al. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J. Immunol. 2006 177 : 130 7.
50. Thomas SR, Salahifar H, Mashima R, Hunt NH, Richardson DR, Stocker R. Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate. J. Immunol. 2001 166 : 6332 40.
51. Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002 297 : 1867 70.
52. Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 2004 114 : 280 90.
53. Fallarino F, Gizzi S, Mosci P, Grohmann U, Puccetti P. Tryptophan catabolism in IDO+ plasmacytoid dendritic cells. Curr. Drug Metab. 2007 8 : 209 16.
54. Lob S, Ebner S, Wagner S, Weinreich J, Schafer R, Konigsrainer A. Are indoleamine-2,3-dioxygenase producing human dendritic cells a tool for suppression of allogeneic T-cell responses? Transplantation 2007 83 : 468 73.
55. Funeshima N, Fujino M, Kitazawa Y, et al. Inhibition of allogeneic T-cell responses by dendritic cells expressing transduced indoleamine 2,3-dioxygenase. J. Gene. Med. 2005 7 : 565 75.
56. Xu S, Ariizumi K, Caceres-Dittmar G, et al. Successive generation of antigen-presenting, dendritic cell lines from murine epidermis. J. Immunol. 1995 154 : 2697 705.
57. Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 2006 176 : 6752 61.
58. Agaugue S, Perrin-Cocon L, Coutant F, Andre P, Lotteau V. 1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J. Immunol. 2006 177 : 2061 71.
59. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005 49 : 15 23.
60. Keskin DB, Marshall B, Munn D, Mellor AL, Gearhart DA. Decreased protein nitration in macrophages that overexpress indoleamine 2, 3-dioxygenase. Cell Mol. Biol. Lett. 2007 12 : 82 102.
61. Wyburn KR, Jose MD, Wu H, Atkins RC, Chadban SJ. The role of macrophages in allograft rejection. Transplantation 2005 80 : 1641 7.
62. Lu CY, Hartono J, Senitko M, Chen J. The inflammatory response to ischemic acute kidney injury: a result of the 'right stuff' in the 'wrong place'? Curr. Opin. Nephrol. Hypertens. 2007 16 : 83 9.